CIK 0001919246 · Non-accelerated filer<br>Smaller reporting company<br>Emerging growth company
Pelthos Therapeutics Inc.
Sign in to watch- Ticker
- PTHS
- Exchange
- NYSE
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Incorporated
- NV
- Entity type
- operating
- EIN
- 863335449
- Phone
- 919-908-2422
- Business address
- 4020 STIRRUP CREEK DRIVE, SUITE 110, DURHAM, NC, 27703
- Former names
- Channel Therapeutics Corp, Chromocell Therapeutics Corp
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $44,939
- in 3 filings, $45K under 10b5-1 plans
Net −$44,939. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2025-07-02 | Francis Knuettel II CFO, Treas & Secty | Grant or award · Stock Option | +102,000 | 145,074 | ||
| 2025-07-02 | Davis Todd C Director | Grant or award · Restricted Stock Units | +19,108 | 36,969 | ||
| 2025-07-02 | Davis Todd C Director | Grant or award · Stock Option | +58,230 | 58,230 | ||
| 2025-07-02 | Friedberg Ezra M Director | Grant or award · Restricted Stock Units | +19,108 | 28,012 | ||
| 2025-07-02 | Friedberg Ezra M Director | Grant or award · Stock Option | +58,230 | 58,230 | ||
| 2025-07-02 | Malamut Richard Director | Grant or award · Restricted Stock Units | +19,108 | 28,012 | ||
| 2025-07-02 | Malamut Richard Director | Grant or award · Stock Option | +58,230 | 58,230 | ||
| 2025-07-01 | Friedberg Ezra M Director | Conversion | +40,000 | $10.00 | $400K | 40,000 |
| 2025-07-01 | Friedberg Ezra M Director | Conversion | +40,000 | $10.00 | $400K | 40,000 |
| 2025-07-01 | Friedberg Ezra M Director | Purchase · Series A Convertible Preferred Stock | +40,000 | 40,000 | ||
| 2025-07-01 | Friedberg Ezra M Director | Purchase · Series A Convertible Preferred Stock | +40,000 | 40,000 | ||
| 2025-07-01 | Friedberg Ezra M Director | Conversion · Series A Convertible Preferred Stock | −40,000 | 0 | ||
| 2025-07-01 | Friedberg Ezra M Director | Conversion · Series A Convertible Preferred Stock | −40,000 | 0 | ||
| 2025-07-01 | Francis Knuettel II Chief Financial Officer | Conversion | +10,000 | $10.00 | $100K | 10,000 |
| 2025-07-01 | Francis Knuettel II Chief Financial Officer | Other acquisition · Series A Convertible Preferred Stock | +10,000 | 10,000 | ||
| 2025-07-01 | Francis Knuettel II Chief Financial Officer | Conversion · Series A Convertible Preferred Stock | −10,000 | 0 | ||
| 2025-07-01 | Davis Todd C Director | Conversion | +1,500,000 | $10.00 | $15.0M | 1,500,000 |
| 2025-07-01 | Davis Todd C Director | Conversion · Series A Convertible Preferred Stock | −15,000 | 3,000 | ||
| 2025-07-01 | Davis Todd C Director | Other acquisition · Series A Convertible Preferred Stock | +31,278.68 | 3,127,868 | ||
| 2025-07-01 | LIGAND PHARMACEUTICALS INC 10% owner | Conversion | +1,500,000 | $10.00 | $15.0M | 1,500,000 |
Page 4 of 6 · 115 trades